Table 2. Summary of randomized control trials comparing DEB-TACE to cTACE in the treatment of HCC.

Study	Patient cohort	No. of BCLC B	Results
Lammer et al 48	201 patients, 93 DEB-TACE and 108 cTACE	69	OR rate: 51.6 vs. 43.5% for DEB-TACE vs. cTACE ( p  = 0.11)
Golfieri et al 49	177 patients, 89 DEB-TACE and 88 cTACE	26	Median TTP of 9 mo in both groups. 1- and 2-y survival rates equivalent between DEB-TACE and cTACE (86.2 and 56.8% vs. 83.5 and 55.4%, p  = 0.949)
Sacco et al 83	67 patients, 33 DEB-TACE and 34 cTACE	11	24-mo overall survival equivalent between DEB-TACE and cTACE (86.8 vs. 83.6%, p  = 0.96)
van Malenstein et al 84	30 patients, 16 DEB-TACE and 14 cTACE	19	Rates of stable disease not significantly different between treatment DEB-TACE and cTACE (77 vs. 92%, p  = 0.54)

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead TACE; HCC, hepatocellular carcinoma; TTP, time to tumor progression.

Note: The number of BCLC stage B patients included in each randomized controlled trial is noted.